Juul suspends advertising and lobbying in US as CEO steps down amid vaping controversy

E-cigarette maker announces changes after string of deaths from mysterious illness linked to vaping 

Wednesday 25 September 2019 14:12
Comments
Also on Wednesday, tobacco giants Altria and Philip Morris International said they were calling off merger talks
Also on Wednesday, tobacco giants Altria and Philip Morris International said they were calling off merger talks

E-cigarette maker Juul is shutting down broadcast, print and digital advertising in the US and ending lobbying efforts in Washington as safety concerns over vaping intensify.

The company on Wednesday said its chief executive was stepping down and will be replaced by a senior executive from Altria, the maker of Marlboro. Altria took a 35 per cent stake in Juul in December at a cost of $13bn (£10.4bn).

Also on Wednesday, one month after announcing that they were in talks over a $200bn merger, the tobacco giants Altria and Philip Morris International said they were calling off those discussions.

Juul has long pushed its e-cigarettes as an alternative for adults looking to wean themselves off tobacco products. But e-cigarettes have become popular among teenagers, and illnesses potentially linked to the product are on the rise.

On Tuesday the governor of Massachusetts declared a public health emergency and ordered a four-month ban on the sale of vaping products in the state, apparently the first action of its kind in the nation. As of Tuesday, 61 cases of potential cases of lung disease related to the use of electronic cigarettes and vaping in Massachusetts had been reported to the state.

Three confirmed cases and two probable Massachusetts cases of vaping-associated pulmonary disease have been reported to the US Centres for Disease Control and Prevention.

Dr. Anne Schuchat, of the CDC, told a congressional subcommittee on Tuesday that she believes “hundreds more” lung illnesses have been reported to health authorities since Thursday, when the CDC put the tally at 530 confirmed and probable cases.

Earlier this month President Donald Trump said that the federal government will act to ban thousands of flavours used in e-cigarettes in response to a recent surge in underage vaping that has alarmed parents, politicians and health authorities nationwide. The Food and Drug Administration will develop guidelines to remove from the market all e-cigarette flavours except tobacco.

The restrictions announced by Trump officials would only apply to nicotine vaping products, which are regulated by the FDA. The FDA has had the authority to ban vaping flavours since 2016, but has previously resisted calls to take that step. Agency officials instead said they were studying if flavours could help smokers quit traditional cigarettes.

But parents, teachers and health advocates have increasingly called for a crackdown on flavours, arguing that they are overwhelmingly to blame for the explosion in underage vaping by American teens, particularly with small, discrete devices such as Juul's.

Federal law prohibits e-cigarette and all other tobacco sales to those under 18.

Altria said that K.C. Crosthwaite will become Juul's new chief executive, replacing Kevin Burns. Crosthwaite served as Altria's chief growth officer.

Crosthwaite said in a prepared statement that Juul has long focused on providing adult smokers with alternatives, but recognized that there's currently “unacceptable levels of youth usage and eroding public confidence in our industry.”

“We must strive to work with regulators, policymakers and other stakeholders, and earn the trust of the societies in which we operate. That includes inviting an open dialogue, listening to others and being responsive to their concerns,” he said.

Altria and Philip Morris said last month that they were in discussions to become a single company, more than a decade after splitting into two as lawsuits mounted.

Altria has exclusively sold Marlboro cigarettes and other tobacco brands in the US, while Philip Morris has handled international sales.

Philip Morris Internationalchief executive Andre Calantzopoulos said Wednesday that the companies will instead focus on launching IQOS in the US. IQOS is a heat-not-burn cigarette alternative made by Philip Morris.

It was Crosthwaite, who will take over Juul, who headed the development of IQOS.

Altria, based in Richmond, Virginia, spun off its international operation in 2008 amid waves of lawsuits and government scrutiny in the U.S. The breakup gave Philip Morris International more leeway to pursue sales growth in emerging markets. Anti-tobacco groups accused the company of manoeuvring to unleash its marketing machine on nonsmoking women and children in poor, developing countries.

Since the split, Philip Morris has churned out new Marlboro-branded products catering to local tastes in Asia, Europe, Latin America and other regions, even as both companies invest in alternatives to traditional cigarettes.

Altria's stock climbed 3.1 per cent before the market opened, while shares of Philip Morris jumped 7.3 per cent.

AP

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in